The nurse would ensure that a patient has an absolute neutrophil count of at least __ /µL before administering Temozolomide (Temodar). Use numbers only.
The correct answer and explanation is:
Correct answer: 1,500
Explanation (approx. 300 words):
Before administering Temozolomide (Temodar)—a chemotherapy drug commonly used to treat brain tumors such as glioblastoma multiforme—it is essential for the nurse or healthcare provider to assess the patient’s absolute neutrophil count (ANC). This is a critical safety measure due to the myelosuppressive effects of Temozolomide, meaning it can significantly lower white blood cell counts, especially neutrophils, which are key components of the immune system.
Neutropenia, or a low neutrophil count, places patients at high risk for severe infections, which can be life-threatening during chemotherapy. An ANC of at least 1,500/µL (or 1.5 × 10⁹/L) is the minimum required threshold before initiating treatment with Temozolomide. If the ANC falls below this level, treatment is usually delayed or withheld until counts recover.
ANC is calculated from a complete blood count (CBC) with differential and is determined using the formula: ANC=Total WBC×(%neutrophils+%bands)/100\text{ANC} = \text{Total WBC} \times (\% \text{neutrophils} + \% \text{bands}) / 100
Monitoring ANC helps ensure the patient can tolerate chemotherapy without experiencing dangerous levels of immunosuppression. In clinical practice, both ANC and platelet counts are typically reviewed before each cycle. Alongside the ANC requirement, platelet counts should also usually be above 100,000/µL for Temozolomide administration.
If the patient’s ANC is below 1,500/µL, dose adjustments, treatment delays, or supportive measures like growth factor support (e.g., filgrastim) may be implemented to improve counts and reduce infection risk.
In summary, the ANC threshold of 1,500/µL ensures safe administration of Temozolomide and helps protect the patient from severe neutropenia-related complications.